Teratogenic Medications

Excerpt

In recent decades, a profound understanding has emerged regarding the potential adverse effects of drugs on fetal physical development when administered to pregnant women. A prime example is thalidomide, an ostensibly innocuous over-the-counter remedy for morning sickness, which can lead to grave consequences for the fetus, including miscarriages and physical deformities. Since 2015, the US Food and Drug Administration (FDA) has enhanced drug safety categorization through the implementation of the Pregnancy and Lactation Labelling Rule (PLLR), replacing the previous "A, B, C, D, X" pregnancy labeling categories. The pivotal factor in determining the nature of these potential defects lies in the gestational age of the embryo at the time of exposure. Consequently, the first trimester, the crucial period of organogenesis, is particularly susceptible to significant malformations. Understanding the mechanisms, risks, and consequences of teratogenic drugs is crucial for healthcare professionals. This activity aims to elucidate the most significant teratogenic medications, shed light on their mechanisms of action, and emphasize the importance of vigilance in the realm of maternal and fetal health.